studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 1089A
of CHC. Older age and receiving treatment were significant
predictors of developing cirrhosis.
Disclosures:
Louis Brooks - Employment: Optum
Mindie H. Nguyen - Advisory Committees or Review Panels: Bristol-Myers
Squibb, Bayer AG, Gilead, Novartis, Onyx; Consulting: Gilead Sciences, Inc.;
Grant/Research Support: Gilead Sciences, Inc., Bristol-Myers Squibb, Novartis
Pharmaceuticals, Roche Pharma AG, Idenix, Hologic, ISIS
The following authors have nothing to disclose: Philip Vutien, Joseph K. Hoang
1806
Progression to liver cirrhosis in patients with chronic
hepatitis C (CHC) in a large United States cohort: a natural
history study
Nghia H. Nguyen 2,1 , Joseph K. Hoang 1 , An K. Le 1 , Changqing
Zhao 1,3 , Christine Y. Chang 1 , Richard H. Le 1 , Mingjuan Jin 1,4 ,
Alina Kutsenko 5 , Lee Ann Yasukawa 6 , Jian Q. Zhang 7 , Susan C.
Weber 6 , Mindie H. Nguyen 1 ; 1 Division of Gastroenterology and
Hepatology, Stanford University Medical Center, Palo Alto, CA;
2 Medicine, University of California, San Diego, San Diego, CA;
3 Department of Cirrhosis,Institute of Liver Disease, Shuguang Hospital,
Shanghai, China; 4 Department of Epidemiology and Biostatistics,
Zhejiang University School of Public Health, Hangzhou,
China; 5 Department of Medicine, Stanford University Medical
Center, Palo Alto, CA; 6 Center for Clinical Informatics, Stanford
University School of Medicine, Palo Alto, CA; 7 Chinese Hospital,
San Francisco, CA
Purpose: Most CHC studies in the U.S. are based on estimates
from simulation models. Our goal was to describe CHC disease
progression to cirrhosis in a real-life cohort from 2 ethnically
diverse U.S. centers. Methods: ICD-9 query identified 9207
consecutive CHC patients in 2005-2014. Analysis was performed
from data obtained via individual chart review in 7105
confirmed CHC cases. Kaplan Meier method was performed
to estimate cumulative incidence of cirrhosis. Cox regression
was performed to identify predictors of disease progression
Results: The majority of our patients were men (62%), had
genotype 1 (69%) and mean age of 55.4±10.7. Treatment
rate was low (13%) in our cohort with the majority of treated
patients having received interferon-based therapy (58%).
Crude incidence for development of cirrhosis was 353.7 per
10,000 person-years. On subgroup analyses, men (vs women)
had a significantly higher overall 5-year cumulative incidence
of cirrhosis (p=0.009) and also when stratified by age (